NEW YORK, Jan. 9, 2018 /PRNewswire/ -- SummaryRead the full report: https://www.reportlinker.com/p03091019
Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure. Although only 4-8% of patients in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Australia) are diagnosed with unresectableStage III or Stage IV metastatic disease, a significant proportion of resectableStage III disease (42-48%) progresses to metastatic melanoma.It is estimated that the value of the melanoma market in the US, five major European markets (5EU: France, Germany, Italy, Spain, and the UK), and Australia in 2016 was about $3.3B. This market is defined as sales of the major branded drugs commonly prescribed for melanoma patients across the 7MM. Among these sales, over 65% (over $2B) were generated in the US, with the 5EU representing the next largest region by sales with an estimated 28% (over $900M).By the end of the forecast period in 2026, melanoma projects sales to rise to about $5.5B in the 7MM, at a modest Compound Annual Growth Rate (CAGR) of just over 5%. In particular, the US melanoma market is expected to grow most rapidly, increasing to over $3.5B (around 70% share) by 2026, at a modest CAGR of 5.8%. Sales in the other regions are expected to increase by the end of the forecast period at CAGRs of around 4% for the 5EU and Australia.It is expected that the approval of 10 pipeline agents would happen over the forecast period; however, few of these are expected to have a major impact on the overall melanoma market. Of these pipeline agents, Incyte's IDO inhibitor epacadostat represents the sales leader with peak-year sales of $383.4M in 2026.The report "PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026", provide overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.Furthermore, this report provides the following -- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.- Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Companies mentioned in this report:AB Science, Amgen, Array BioPharma, AVAX Technologies, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Merck & Co, NovartisScope- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.- Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global melanoma market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Read the full report: https://www.reportlinker.com/p03091019
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/by-the-end-of-the-forecast-period-in-2026-melanoma-projects-sales-to-rise-to-about-55b-in-the-7mm-at-a-modest-compound-annual-growth-rate-cagr-of-just-over-5-300580232.html
SOURCE Reportlinker
